Polymerase chain response (PCR) is by far probably the most generally used methodology of nucleic acid amplification and has likewise been employed for a plethora of diagnostic functions. Nonetheless, multiplexed PCR-based detection schemes have hitherto been largely restricted by technical challenges related to nonspecific interactions and different limitations inherent to conventional fluorescence-based assays.
Right here, we describe a novel technique for multiplexed PCR-based evaluation known as Ligation-eNabled fluorescence-Coding PCR (LiNC PCR) that exponentially enhances the multiplexing functionality of ordinary fluorescence-based PCR assays. The approach depends upon a easy, preliminary ligation response by which goal DNA sequences are transformed to PCR template molecules with distinct endpoint fluorescence signatures.
Common TaqMan probes are used to create target-specific multicolor fluorescence alerts that may be readily decoded to establish amplified targets of curiosity. We exhibit the LiNC PCR approach by implementing a two-color-based assay for detection of 10 ovarian most cancers epigenetic biomarkers at analytical sensitivities as little as 60 template molecules with no detectable goal cross-talk. General, LiNC PCR gives a easy and cheap methodology for reaching high-dimensional multiplexing that may be carried out in manifold molecular diagnostic functions.
Effectivity of the novel quenching-probe PCR methodology to detect 23S rRNA mutations in kids with Mycoplasma pneumoniae an infection
An automatic speedy molecular diagnostic equipment (Sensible Gene Myco) was just lately developed for particular person detection of Mycoplasma pneumoniae (MP) genes. This new testing strategy requires no particular gear and abilities and will be accomplished inside 50 min. We prospectively evaluated this diagnostic equipment, together with different typical checks, for pneumonia analysis in kids.
Samples from 98 kids (50 boys and 48 ladies; aged 1-14 years; imply: 4.7 ± 2.1 years; median: Four years) clinically identified with pneumonia had been examined for MP utilizing real-time polymerase chain response (RT-PCR) as a reference methodology. Outcomes from three molecular diagnostic checks, serum anti-MP antibodies, and MP tradition had been in comparison with RT-PCR information.
Among the many 98 kids, 38 had been optimistic for MP. All molecular diagnostic outcomes confirmed full concordance with the RT-PCR information. The sensitivity of the tradition was 64%, whereas the sensitivities of the ImmunoCard Mycoplasma and SERODIA Myco II kits had been decrease (39% and 29%, respectively). Moreover, a major optimistic correlation was discovered between MP copy numbers and the tradition take a look at sensitivity (r = 0.95, p = 0.048).
Macrolide-resistance mutations within the 23S ribosomal RNA gene had been detected in 24 of 38 kids utilizing Sensible Gene Myco based mostly on quenching-probe PCR, which was confirmed by direct sequencing, revealing all mutations as A2063G. That is the primary examine to judge the medical utility of the Sensible Gene Myco equipment, demonstrating that it’s a quick and dependable methodology to help well timed therapeutic choices in kids with MP pneumonia.
Arboviruses within the Astrakhan area of Russia for 2018 season: The event of multiplex PCR assays and evaluation of mosquitoes, ticks, and human blood sera
The Astrakhan area of Russia is endemic for the variety of arboviruses. On this paper, we describe the outcomes of the detection of the listing of uncared for arboviruses within the Astrakhan area for the 2018 season. For the aim of the examine in-house PCR assays for detection of 18 arboviruses have been developed and validated utilizing arboviruses obtained from Russian State Assortment of Viruses.
Swimming pools of ticks (n = 463) and mosquitoes (n = 312) in addition to 420 samples of human sufferers sera have been collected and analyzed. Utilizing developed multiplex real-time PCR assays we had been in a position to detect RNA of eight arboviruses (Crimean-Congo hemorrhagic fever virus, Dhori (Batken pressure) virus, Batai virus, Tahyna virus, Uukuniemi virus, Inkoo virus, Sindbis virus and West Nile fever virus). All found viruses are able to infecting people inflicting fever and in some circumstances extreme kinds with hemorrhagic or neurologic signs.
From PCR-positive samples, we had been in a position to get well one isolate every of Dhori (Batken pressure) virus and Crimean-Congo hemorrhagic fever virus which had been additional characterised by next-generation sequencing. The genomic sequences of recognized Dhori (Batken pressure) virus pressure signify probably the most full genome of Batken virus pressure amongst beforehand reported.
Haplotype-specific PCR for NAT2 diplotyping
N-acetyltransferase 2 (NAT2) is an enzyme that acetylates many sorts of medicine, together with the antituberculosis drug isoniazid. The NAT2 gene is extremely various throughout populations. A person will be categorised as having a sluggish acetylator (SA), an intermediate acetylator (IA), or a speedy acetylator (RA) phenotype based mostly on its two haplotypes (diplotype) of NAT2. SA people are at the next danger for isoniazid-induced hepatitis, whereas the RA phenotype contributes to failure in tuberculosis therapy.
With the ability to predict particular person NAT2 phenotypes is necessary for dose adjustment of isoniazid. NAT2 haplotypes are generally decided by way of an oblique methodology of statistical haplotype inference from SNP genotyping. Right here, we report a direct NAT2 haplotyping methodology utilizing haplotype-specific PCR (HS-PCR) for the 6 mostly discovered NAT2 haplotypes: NAT2*4, NAT2*5B, NAT2*6A, NAT2*7B, NAT2*12A, and NAT2*13A. Validation of this HS-PCR methodology by way of comparability with a sequencing methodology in 650 Thai DNA samples (107 RA, 279 IA, and 264 SA samples) confirmed a concordance charge for diplotype calls of 99.23% (645/650 samples).
 CP-724714 |
|
A2412-5 |
ApexBio |
5 mg |
EUR 68 |
|
|
|
Description: JAK/STAT Signaling|EGFR#Tyrosine Kinase|EGFR#Tyrosine Kinase|HER2 |
CP-724714 |
|
A2412-5.1 |
ApexBio |
10 mM (in 1mL DMSO) |
EUR 73.6 |
|
|
|
Description: JAK/STAT Signaling|EGFR#Tyrosine Kinase|EGFR#Tyrosine Kinase|HER2 |
 CP 471474 |
|
A4435-1 |
ApexBio |
1mg |
EUR 40 |
|
|
|
Description: Proteases|MMP |
CP 471474 |
|
A4435-10 |
ApexBio |
10 mg |
EUR 176 |
|
|
|
Description: Proteases|MMP |
CP 471474 |
|
A4435-5 |
ApexBio |
5mg |
EUR 104 |
|
|
|
Description: Proteases|MMP |
CP 471474 |
|
A4435-50 |
ApexBio |
50 mg |
EUR 842 |
|
|
|
Description: Broad spectrum MMP inhibitor |
 CP-809101 |
|
A3330-10 |
ApexBio |
10 mg |
EUR 137.6 |
|
|
|
Description: Neuroscience|5-HT Receptor |
CP-809101 |
|
A3330-50 |
ApexBio |
50 mg |
EUR 591.2 |
|
|
|
Description: Neuroscience|5-HT Receptor |
 CP-91149 |
|
A8403-10 |
ApexBio |
10 mg |
EUR 104.8 |
|
|
|
Description: Metabolism|Phospholipase |
CP-91149 |
|
A8403-25 |
ApexBio |
25 mg |
EUR 210.4 |
|
|
|
Description: Metabolism|Phospholipase |
CP-91149 |
|
A8403-5 |
ApexBio |
5 mg |
EUR 88 |
|
|
|
Description: Metabolism|Phospholipase |
 CP-466722 |
|
A8625-10 |
ApexBio |
10 mg |
EUR 136 |
|
|
|
Description: Cell Cycle/Checkpoint|ATM/ATR#DNA Damage/DNA Repair|ATM/ATR |
CP-466722 |
|
A8625-5 |
ApexBio |
5 mg |
EUR 88 |
|
|
|
Description: Cell Cycle/Checkpoint|ATM/ATR#DNA Damage/DNA Repair|ATM/ATR |
CP-466722 |
|
A8625-50 |
ApexBio |
50 mg |
EUR 373.6 |
|
|
|
Description: Cell Cycle/Checkpoint|ATM/ATR#DNA Damage/DNA Repair|ATM/ATR |
 CP Antibody |
|
45875-100ul |
SAB |
100ul |
EUR 302.4 |
CP Antibody |
|
45875-50ul |
SAB |
50ul |
EUR 224.4 |
CP Antibody |
|
46543 |
SAB |
100ul |
EUR 319 |
CP Antibody |
|
46543-100ul |
SAB |
100ul |
EUR 302.4 |
CP Antibody |
|
DF9369-100ul |
Affinity Biosciences |
100ul |
EUR 168 |
|
|
|
Description: WB,IHC,IF/ICC,ELISA(peptide) |
CP Antibody |
|
DF9369-200ul |
Affinity Biosciences |
200ul |
EUR 210 |
|
|
|
Description: WB,IHC,IF/ICC,ELISA(peptide) |
 CP-640186 |
|
B3585-10 |
ApexBio |
10 mg |
EUR 156 |
|
|
|
Description: isozyme-nonselective acetyl-CoA carboxylase (ACCase) inhibitor |
CP-640186 |
|
B3585-2 |
ApexBio |
2 mg |
EUR 64 |
|
|
|
Description: isozyme-nonselective acetyl-CoA carboxylase (ACCase) inhibitor |
CP-640186 |
|
B3585-5 |
ApexBio |
5 mg |
EUR 96 |
|
|
|
Description: isozyme-nonselective acetyl-CoA carboxylase (ACCase) inhibitor |
CP-640186 |
|
B3585-50 |
ApexBio |
50 mg |
EUR 616 |
|
|
|
Description: isozyme-nonselective acetyl-CoA carboxylase (ACCase) inhibitor |
 CP 80633 |
|
B7162-.5 |
ApexBio |
500ug |
EUR 40 |
|
Description: Metabolism|PDE |
CP 80633 |
|
B7162-1 |
ApexBio |
1mg |
EUR 56 |
|
Description: Metabolism|PDE |
CP 80633 |
|
B7162-10 |
ApexBio |
10 mg |
EUR 392 |
|
|
|
Description: Metabolism|PDE |
CP 80633 |
|
B7162-5 |
ApexBio |
5mg |
EUR 228 |
|
Description: Metabolism|PDE |
CP 80633 |
|
B7162-50 |
ApexBio |
50 mg |
EUR 1019 |
|
|
|
Description: PDE4 inhibitor |
 CP 154526 |
|
B7185-1 |
ApexBio |
1 mg |
EUR 66.4 |
|
|
|
Description: GPCR/G protein|CRF1 Receptors |
CP 154526 |
|
B7185-5 |
ApexBio |
5 mg |
EUR 103.2 |
|
|
|
Description: GPCR/G protein|CRF1 Receptors |
 CP 96345 |
|
B7213-10 |
ApexBio |
10 mg |
EUR 472 |
|
|
|
Description: Neuroscience|Substance P/NK1 Receptor |
CP 96345 |
|
B7213-50 |
ApexBio |
50 mg |
EUR 1482.4 |
|
|
|
Description: Neuroscience|Substance P/NK1 Receptor |
 CP 316819 |
|
B5448-10 |
ApexBio |
10 mg |
EUR 495.2 |
|
|
|
Description: Metabolism|Phospholipase |
CP 316819 |
|
B5448-50 |
ApexBio |
50 mg |
EUR 1493.6 |
|
|
|
Description: Metabolism|Phospholipase |
 CP 20961 |
|
B5474-1 |
ApexBio |
1mg |
EUR 44 |
|
Description: Others|Miscellaneous Compounds |
CP 20961 |
|
B5474-10 |
ApexBio |
10 mg |
EUR 156 |
|
|
|
Description: Others|Miscellaneous Compounds |
CP 20961 |
|
B5474-25 |
ApexBio |
25mg |
EUR 340 |
|
Description: Others|Miscellaneous Compounds |
CP 20961 |
|
B5474-5 |
ApexBio |
5mg |
EUR 108 |
|
Description: Others|Miscellaneous Compounds |
CP 20961 |
|
B5474-50 |
ApexBio |
50 mg |
EUR 952 |
|
|
|
Description: non-immunogenic adjuvant |
 CP-673451 |
|
B2173-10 |
ApexBio |
10 mg |
EUR 180 |
|
|
|
Description: Tyrosine Kinase|VEGFR |
CP-673451 |
|
B2173-200 |
ApexBio |
200 mg |
EUR 1672 |
|
|
|
Description: Tyrosine Kinase|VEGFR |
CP-673451 |
|
B2173-5 |
ApexBio |
5 mg |
EUR 95.2 |
|
|
|
Description: Tyrosine Kinase|VEGFR |
CP-673451 |
|
B2173-5.1 |
ApexBio |
10 mM (in 1mL DMSO) |
EUR 128 |
|
|
|
Description: Tyrosine Kinase|VEGFR |
CP-673451 |
|
B2173-50 |
ApexBio |
50 mg |
EUR 543.2 |
|
|
|
Description: Tyrosine Kinase|VEGFR |
 CP 135807 |
|
B7497-10 |
ApexBio |
10 mg |
EUR 270.4 |
|
|
|
Description: GPCR/G protein|5-HT Receptor |
CP 135807 |
|
B7497-50 |
ApexBio |
50 mg |
EUR 1096 |
|
|
|
Description: GPCR/G protein|5-HT Receptor |
 CP 775146 |
|
B7609-1 |
ApexBio |
1mg |
EUR 40 |
|
Description: Metabolism|PPAR |
CP 775146 |
|
B7609-10 |
ApexBio |
10 mg |
EUR 268 |
|
|
|
Description: Metabolism|PPAR |
CP 775146 |
|
B7609-25 |
ApexBio |
25mg |
EUR 588 |
|
Description: Metabolism|PPAR |
CP 775146 |
|
B7609-5 |
ApexBio |
5mg |
EUR 156 |
|
Description: Metabolism|PPAR |
CP 775146 |
|
B7609-50 |
ApexBio |
50 mg |
EUR 1234 |
|
|
|
Description: PPARα agonist |
CP Antibody |
|
CSB-PA361096XA01OAM-02mg |
Cusabio |
0.2mg |
Ask for price |
|
|
|
Description: Recombinant Odontoglossum ringspot virus (isolate Japan) (ORSV) CP protein |
CP Antibody |
|
CSB-PA361096XA01OAM-10mg |
Cusabio |
10mg |
Ask for price |
|
|
|
Description: Recombinant Odontoglossum ringspot virus (isolate Japan) (ORSV) CP protein |
CP Antibody |
|
1-CSB-PA14599A0Rb |
Cusabio |
-
Ask for price
-
Ask for price
|
|
|
|
|
Description: A polyclonal antibody against CP. Recognizes CP from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC; Recommended dilution: IHC:1:20-1:200 |
CP Antibody |
|
CSB-PA886137XA01FRS-02mg |
Cusabio |
0.2mg |
Ask for price |
|
|
|
Description: Recombinant Ribgrass mosaic virus (RMV) CP protein |
CP Antibody |
|
CSB-PA886137XA01FRS-10mg |
Cusabio |
10mg |
Ask for price |
|
|
|
Description: Recombinant Ribgrass mosaic virus (RMV) CP protein |
 CP-447697 |
|
HY-112199 |
MedChemExpress |
10 mg |
EUR 568.19 |
|
Description: CP-447697 is a lipophilic C5a receptor antagonist with an IC50 value of 31 nM. CP-447697 can be used for the research of inflammation[1]. |
 CP-195543 |
|
HY-112742 |
MedChemExpress |
Get quote |
Ask for price |
|
Description: CP-195543 is a potent, selective and orally active leukotriene B4 (LTB4) receptor antagonist with IC50s of 6.8, 37.0 nM for human neutrophils and murine spleen membranes, respectively. CP-195543 blocks CD11b up-regulation. CP-195543 inhibits LTB4-mediated neutrophil infiltration[1]. |
 CP-67804 |
|
HY-113642 |
MedChemExpress |
Get quote |
Ask for price |
|
Description: CP-67804 is a quinolone derivative, is a topoisomerase II-targeted agent. CP-67804 effectively enhances DNA cleavage mediated by eukaryotic topoisomerase II. CP-67804 has potential as an antineoplastic agent[1]. |
 CP-346086 |
|
HY-113955 |
MedChemExpress |
10 mg |
EUR 270.57 |
|
Description: CP-346086 is a potent and orally active microsomal triglyceride transfer protein (MTP) inhibitor, with an IC50 of 2.0 nM for human and rodent MTP. CP-346086 can lower plasma cholesterol and triglycerides in vivo[1]. |
 CP-07 |
|
HY-149495 |
MedChemExpress |
Get quote |
Ask for price |
|
Description: CP-07 is a potent and selective PROTACCDK9 degrader (DC50: 43 nM). CP-07 inhibits 22RV1 cell proliferation (IC50: 62 nM) and colony formation by down-regulating Mcl-1 and c-Myc. CP-07 inhibits 22RV1 xenograft tumor growth. CP-07 can be used for research of prostate cancer[1]. |
 CP-506 |
|
HY-149769 |
MedChemExpress |
Get quote |
Ask for price |
|
Description: CP-506 (compound 26) is an anticancer compound and a substrate for nitroreductase and CYP oxidoreductases. CP-506 has anticancer activity[1]. |
CP-640186 |
|
HY-15259 |
MedChemExpress |
100mg |
EUR 519.49 |
|
Description: CP-640186 is an orally active and cell-permeable Acetyl-CoA carboxylase (ACC) inhibitor with IC50s of 53 nM and 61 nM for rat liver ACC1 and rat skeletal muscle ACC2 respectively. Acetyl-CoA carboxylase (ACC) is a key enzyme of fatty acid metabolism that enables the synthesis of malonyl-CoA. CP-640186 can also stimulate muscle fatty acid oxidation[1][2]. |
CP-91149 |
|
HY-13525 |
MedChemExpress |
10 mg |
EUR 324.68 |
|
Description: CP-91149 is a GP (glycogen phosphorylase) inhibitor. CP-91149 promotes glycogen resynthesis, but not its overaccumulation. CP-91149 has the potential for Type II (insulin-dependent) diabetes study[1]. |
 CP-96486 |
|
HY-100316 |
MedChemExpress |
1mg |
EUR 2128.8 |
|
Description: CP-96486 is a potent and orally active leukotriene D4 (LTD4)/platelet activating factor (PAF) receptor antagonist with Kis of 20 and 24 nM, respectively. |
 CP 375 |
|
HY-100332 |
MedChemExpress |
1mg |
EUR 1870.8 |
|
Description: CP 375 is a Fe3+ chelating agent, with a log K1 value of 14.50. |
 CP-409092 |
|
HY-101639 |
MedChemExpress |
Get quote |
Ask for price |
|
Description: CP-409092 is a partial agonist of GABAA receptor, with anti-anxiety activity[1]. |
 CP-135807 |
|
HY-103092 |
MedChemExpress |
5 mg |
EUR 280.31 |
|
Description: CP-135807 is an orally active and selective 5-HT1D agonist (IC50=3.1 nM), bovine). CP-135807 mediates central psychoactivity and can be used in antidepressant research[1][2]. |
 CP-122288 |
|
HY-105192 |
MedChemExpress |
Get quote |
Ask for price |
|
Description: CP-122288, a highly potent inhibitor of neurogenic inflammation, can be used in migraine study[1]. |
 CP-113818 |
|
HY-105445 |
MedChemExpress |
1 mg |
EUR 1466.47 |
|
Description: CP-113818 is a potent cholesterol acyltransferase (ACAT) inhibitor. CP-113818 can be used for the research of Alzheimer's disease[1]. |
 CP-544439 |
|
HY-107013 |
MedChemExpress |
Get quote |
Ask for price |
|
Description: CP-544439 is a potent and orally active matrix metalloproteinase-13 (MMP-13) inhibitor with an IC50 of 0.75 nM[1][2]. |
 CP-20961 |
|
HY-107634 |
MedChemExpress |
10 mg |
EUR 623.39 |
|
Description: CP-20961 is a potent synthetic non-immunogenic adjuvant that induces arthritis[1][2]. |
 CP-96,345 |
|
HY-108482 |
MedChemExpress |
10mg |
EUR 466.46 |
|
Description: CP-96,345 is a specific, highly potent, and orally active tachykinin and substance P receptor non-peptide inhibitor. CP-96,345 prevents the drop in blood pressure evoked by substance P and neurokinin A. CP-96,345 can be used for researching neurogenic inflammation[1]. |
 CP-775146 |
|
HY-108571 |
MedChemExpress |
5 mg |
EUR 389.62 |
|
Description: CP-775146 is a selective PPARα agonist that binds strongly to the PPARα ligand. CP-775146 efficiently alleviates obesity-induced liver damage, prevents lipid accumulation by activating the liver fatty acid β-oxidation pathway[1]. |
 CP-316819 |
|
HY-108615 |
MedChemExpress |
10 mg |
EUR 671.01 |
|
Description: CP 316819 is a potent glycogen phosphorylase (GPase) inhibitor with antihyperglycemic effect (IC50 values are 17 and 34 nM against human skeletal muscle glycogen phosphorylase (huSMGPa) and liver glycogen phosphorylase (huLGPa) respectively).CP 316819 causes glycogen accumulation under normoglycemic conditions but permits glycogen utilization when glucose concentrations are low.CP-316819 prevents neuronal cell death and maintains brain electrical currents[1][2]. |
 CP-67015 |
|
HY-109855 |
MedChemExpress |
Get quote |
Ask for price |
|
Description: CP-67015, a quinolone antibiotic, is a potent topoisomerase II inhibitor. CP-67015 is a positive direct-acting mutagen in mammalian cells with both gene and chromosomal level effects[1]. |
CP-466722 |
|
HY-11002 |
MedChemExpress |
50mg |
EUR 452.39 |
|
Description: CP-466722 is a rapidly reversible inhibitor of ATM, with an IC50 of 0.41 μM, and has no effects on PI3K or closely related PI3K-like protein kinase (PIKK) family members. |
CP-809101 |
|
HY-15543 |
MedChemExpress |
50mg |
EUR 854.4 |
|
Description: CP-809101 is a potent and highly selective 5-HT2C receptor agonist, with pEC50s of 9.96, 7.19 and 6.81 M for human 5HT2C, 5HT2B and 5HT2A receptor. CP-809101 inhibits conditioned avoidance responding in rats and antagonizes both PCP (phencyclidine hydrochloride)- and d-amphetamine-induced hyperactivity. CP-809101 also reduces food and nicotine dependence in rats, can be used in studies of antipsychotic and nicotine dependence[1][2]. |
 CP-609754 |
|
HY-16373 |
MedChemExpress |
10 mg |
EUR 270.57 |
|
Description: CP-609754 (LNK-754) is a potent and reversible farnesyltransferase inhibitor with potential anticancer activity.The IC50 for inhibiting farnesylation of recombinant human H-Ras is 0.57 ng/mL and recombinant K-Ras is 46 ng/mL[1]. CP-609754 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups. |
 CP-610431 |
|
HY-16946 |
MedChemExpress |
Get quote |
Ask for price |
|
Description: CP-610431 is a reversible, ATP-uncompetitive, isozyme-nonselective acetyl-CoA carboxylase (ACC) inhibitor. CP-610431 inhibits ACC1 and ACC2 with IC50s of ~50 nM. CP-610431 can be used for the research of metabolic syndrome[1]. |
 CP-465022 |
|
HY-18663 |
MedChemExpress |
10 mg |
EUR 638.54 |
|
Description: CP-465022 is a potent, and selective noncompetitive AMPA receptor antagonist with anticonvulsant activity. CP-465022 is against Kainate-induced response with an IC50 of 25 nM in rat cortical neurons. CP-465022 provides a new tool to investigate the role of AMPA receptors in physiological and pathophysiological processes[1][2]. |
 CP-66948 |
|
HY-19048 |
MedChemExpress |
20mg |
EUR 5763.6 |
|
Description: CP-66948 is a histamine H2-receptor antagonist with gastric antisecretory activity and mucosal protective properties. |
 CP-105696 |
|
HY-19193 |
MedChemExpress |
10 mg |
EUR 173.16 |
|
Description: CP-105696 is a potent and selective Leukotriene B4 Receptor antagonist, with an IC50 of 8.42 nM. |
 CP-10 |
|
HY-125835 |
MedChemExpress |
10 mg |
EUR 2868.01 |
|
Description: CP-10 is a PROTAC connected by ligands for Cereblon and CDK, with highly selective, specific, and remarkable CDK6 degradation (DC50=2.1 nM). It inhibits proliferation of several haematopoietic cancer cells with impressive potency including multiple myeloma, and can still degrades mutated and overexpressed CDK6[1]. |
 CP-547632 |
|
HY-13302 |
MedChemExpress |
10mM/1mL |
EUR 335.5 |
|
Description: CP-547632 is an orally active, ATP-competitive and potent VEGFR-2 and FGF kinases inhibitor with IC50s of 11 nM and 9 nM, respectively. CP-547632 is selective for VEGFR2 and bFGF over EGFR, PDGFRβ, and related tyrosine kinases (TKs). CP-547632 has antitumor efficacy[1]. |
CP Antibody |
|
E046543 |
EnoGene |
100μg/100μl |
EUR 255 |
|
Description: Available in various conjugation types. |
CP Antibody |
|
E19-9369-1 |
EnoGene |
50ug/50ul |
EUR 145 |
|
Description: Available in various conjugation types. |
CP Antibody |
|
E19-9369-2 |
EnoGene |
100ug/100ul |
EUR 225 |
|
Description: Available in various conjugation types. |
 CP 226269 |
|
HY-116082 |
MedChemExpress |
1 mg |
EUR 72.51 |
|
Description: CP 226269 is a potent dopamine D4 receptor agonist that induces calcium flux with EC50 of 32.0 nM. CP 226269 can be used in the research of schizophrenia and other related diseases[1]. |
 CP-74006 |
|
HY-118639 |
MedChemExpress |
100 mg |
EUR 54.11 |
|
Description: CP-74006 (compound11h) is a selective Cyclooxygenase-1 inhibitor[1]. |
 CP-424174 |
|
HY-119721 |
MedChemExpress |
2 mg |
EUR 179.66 |
|
Description: CP-424174 is a reversible inhibitor against IL-1β processing with an IC50 of 210 nM.CP-424174 indirectly inhibits NLRP3[1]. |
CP-673451 |
|
HY-12050 |
MedChemExpress |
5mg |
EUR 865.81 |
|
Description: CP-673451 is a potent and selective inhibitor of PDGFR with IC50s of 10 and 1 nM for PDGFRα and PDGFRβ, respectively. |
CP 154526 |
|
HY-12130 |
MedChemExpress |
Get quote |
Ask for price |
|
Description: CP 154526, a non peptidic corticotropin releasing factor receptor antagonist attenuates fever and exhibits anxiolytic-like activity[1]. |
 CP-532623 |
|
HY-123039 |
MedChemExpress |
10 mg |
EUR 395.03 |
|
Description: CP-532623 is a CETP inhibitor and elevates high-density lipoprotein cholesterolion. CP-532623 is a close structural analogue of Torcetrapib. CP-532623 has highly lipophilic properties[1][2][3]. |
The discordant ends in 5 samples had been resulting from Three uncommon NAT2 haplotypes: NAT*5C (n = 3), NAT2*7C (n = 1), and NAT2*11A (n = 1). This novel HS-PCR methodology permits direct NAT2 diplotyping, enabling the implementation of NAT2 acetylator phenotypes in medical pharmacogenetic testing.
